Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
Status:
Terminated
Trial end date:
2021-05-20
Target enrollment:
Participant gender:
Summary
A-REPEAT (Anti-Epidermal Growth Factor Receptor -EGFR- rechallenge and plasma genotyping of
patients with advanced colorectal tumors) is a Greek, investigator-initiated, single arm
open-label phase II study of anti-EGFR therapy rechallenge in combination with chemotherapy
in patients with advanced colorectal cancer. Patients with a metastatic, histologically
proven colorectal carcinoma RAS wild type will be treated with a combination of panitumumab
and third-line irinotecan-based or oxaliplatin-based chemotherapy (FOLFOX,FOLFIRI or
irinotecan monotherapy).